Compare NBTX & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTX | KBDC |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 962.3M |
| IPO Year | 2020 | N/A |
| Metric | NBTX | KBDC |
|---|---|---|
| Price | $24.85 | $14.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $26.00 | $15.80 |
| AVG Volume (30 Days) | 22.3K | ★ 342.0K |
| Earning Date | 04-01-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 13.60% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,930,711.00 | N/A |
| Revenue This Year | N/A | $193.84 |
| Revenue Next Year | $145.24 | $9.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.95 | $13.06 |
| 52 Week High | $30.35 | $17.99 |
| Indicator | NBTX | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 41.91 |
| Support Level | $22.76 | $13.52 |
| Resistance Level | $25.55 | $14.50 |
| Average True Range (ATR) | 1.13 | 0.34 |
| MACD | 0.40 | 0.01 |
| Stochastic Oscillator | 72.91 | 41.63 |
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.